Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Altimmune Inc
(NQ:
ALT
)
6.100
-0.130 (-2.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altimmune Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
B. Riley Securities Maintains Buy Rating for Altimmune: Here's What You Need To Know
August 12, 2022
B. Riley Securities has decided to maintain its Buy rating of Altimmune (NASDAQ:ALT) and raise its price target from $21.00 to $26.00. Shares of Altimmune are trading up 23.53% over the last 24...
Via
Benzinga
LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday
August 12, 2022
WeTrade Group, Inc. (NASDAQ: WETG) jumped 46% to $20.56 after the company announced it entered into a sales agreement with Parkway Medical Limited to sell monkeypox virus test kits and antigen tests...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 03, 2022
Via
Benzinga
7 Biotech Stocks to Buy for Q3
July 18, 2022
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential.
Via
InvestorPlace
Altimmune: Q1 Earnings Insights
May 12, 2022
Altimmune (NASDAQ:ALT) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Altimmune: Q4 Earnings Insights
March 15, 2022
Altimmune (NASDAQ:ALT) reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Altimmune's Earnings Outlook
March 11, 2022
Altimmune (NASDAQ:ALT) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts estimate...
Via
Benzinga
89 Biggest Movers From Friday
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity
January 31, 2022
The FDA has cleared Altimmune Inc's (NASDAQ:
Via
Benzinga
69 Biggest Movers From Yesterday
June 10, 2022
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday.
Via
Benzinga
Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know
May 18, 2022
Piper Sandler has decided to maintain its Overweight rating of Altimmune (NASDAQ:ALT) and lower its price target from $34.00 to $25.00. Shares of Altimmune are trading down 0.57% over the last 24...
Via
Benzinga
110 Biggest Movers From Friday
May 16, 2022
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Via
Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
May 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
May 09, 2022
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:...
Via
Benzinga
Altimmune Earnings Perspective: Return On Capital Employed
March 16, 2022
According to Benzinga Pro data, during Q4, Altimmune (NASDAQ:ALT) posted sales of $3.28 million. Earnings were up 28.71%, but Altimmune still reported an overall loss of $23.89...
Via
Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For March 14, 2022
March 14, 2022
Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (...
Via
Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
March 13, 2022
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
December 30, 2021
Gainers Kiora Pharmaceuticals (NASDAQ:KPRX
Via
Benzinga
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
December 29, 2021
Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current
Via
Talk Markets
ALTIMMUNE INC (ALT) Q3 2021 Earnings Call Transcript
November 11, 2021
ALT earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
52 Biggest Movers From Yesterday
September 30, 2021
Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) jumped 36.2% to close at $3.91. Smart Share...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
September 29, 2021
Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana...
Via
Benzinga
33 Stocks Moving In Wednesday's Mid-Day Session
September 29, 2021
Gainers Paltalk, Inc. (NASDAQ: PALT) shares climbed 37% to $7.18. NuCana plc (NASDAQ: NCNA) jumped 31.4% to $3.1150. The FDA granted Fast Track designation to NuCana’s...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
September 29, 2021
Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6...
Via
Benzinga
H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off
September 28, 2021
H.C. Wainwright said that Altimmune Inc (NASDAQ:
Via
Benzinga
ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34
September 28, 2021
Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock.
Via
InvestorPlace
Dow Set to Snap Win Streak as Tech Sector Weighs
September 28, 2021
The Dow Jones Industrial Average looks ready to snap its four-day win streak, as the tech sector's recent rout catches up with the index, which was last seen down 419 points.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Why Altimmune Stock Is Under Pressure Today
September 28, 2021
Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.
Via
The Motley Fool
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.